Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.

Fiche publication

Date publication

octobre 2022

Journal

European journal of heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36303266

Résumé

Spironolactone is currently used in a large proportion of patients with heart failure and preserved ejection fraction (HFpEF), yet its effects on cardiac structure and function in a large population has not been well established.